PEDIATRIC ONCOLOGY GROUP PROGRAM-UNIVERSITY OF FLORIDA

佛罗里达大学儿科肿瘤学小组项目

• 批准号: 3557049
• 负责人: SAMUEL GROSS
• 金额: $ 10.85万
• 依托单位: UNIVERSITY OF FLORIDA
• 依托单位国家: 美国
• 财政年份: 1981
• 资助国家: 美国
• 起止时间: 1981-01-01 至 1986-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3557049
• 关键词: cancer registry /resource; cancer rehabilitation mental health service; cancer risk; child (0-11); cooperative study; cyclophosphamide; drug metabolism; fluorouracil; human T cell leukemia; human subject; human therapy evaluation; lymphoma; methotrexate; neoplasm /cancer chemotherapy; neoplasm /cancer immunology; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; neuroblastoma; osteosarcoma; pediatric neoplasm /cancer; pediatric pharmacology; retinoblastoma; rhabdomyosarcoma

Included in the mandate for the next generation of cooperative group efforts is the need to extend prior POG studies, as well as those from other institutions and groups, on the nature and classification of tumor biology and to expand such efforts into feasible phase II/III studies. Histologic, immunologic and natural history classifications of acute lymphoblastic leukemia have enabled investigators to develop therapeutic efforts tailored to address specific entities in this regard, i.e., high risk (WBC greater than 50,000/mm., T-cell), low risk, occult disease, extramedullary relapse. For certain categories and subclassifications, it is apparent that such therapeutic efforts have resulted in dramatic improvement, as in Wilms' tumor and rhabdomysarcoma; in others, the results have been disappointing, i.e., Ewing's sarcoma, stage III/IV neuroblastoma, brain tumors, osteogenic sarcoma, high risk ALL, and AML. Pharmacokinetic studies of megadose therapy and data derived from transplantation biology and related phase II studies provides opportunities heretofore not readily available to employ high-dosage regimens with temporal monitoring of drug kinetics so as to utilize pharmacologic rescue regimens, as in high dose MTX with folinic acid rescue, or marrow infusion following ablative therapy. The bone marrow transplant unit at the University of Florida will continue (1) to conduct allogeneic transplantation studies of high risk ALL, and AML, in first remission designed to ask questions concerning conditioning regimens and immune recovery, and (2) to utilize autologous marrow rescue following megadose therapy coupled with pharmacokinetic data for relapsing/resistant solid tumors, i.e., Ewing's sarcoma, neuroblastoma, non-Hodgkin's lymphoma, brain tumor, Hodgkin's Disease and Wilms' tumor. Research endeavors will include correlating histologic and immunologic characteristics with therapy responses as in ALL and neuroblastomas. Whole group endeavors will consist of active participation in ongoing and newly developed protocols including a multi-institution osteogenic sarcoma study. Efforts have also been rewarding in scientifically involved investigation including surgeons and radiotherapists as well as identifying additional satellites representing a further accrual of 35-40 patients/year, establishing a rural referral for maintaining home care and medical center communication, and establishing a comprehensive psychosocial support system.

包括在下一代合作小组的任务中 努力是需要扩展先前的POG研究，以及 其他机构和群体，关于肿瘤的性质和分类 生物学并将这种工作扩展到可行的II/III期研究中。 急性的组织学，免疫和自然史分类 淋巴细胞白血病使研究人员得以发展治疗 为解决这方面的特定实体而定制的努力，即高 风险（WBC大于50,000/mm，T细胞），低风险，神秘疾病， 耗尽的复发。 对于某些类别和亚分类， 显然，这种治疗努力导致了戏剧性 改善，如威尔姆斯的肿瘤和横纹肌肉瘤所示；在其他情况下，结果 令人失望的是，即尤因的肉瘤，第三阶段/IV神经母细胞瘤， 脑肿瘤，成骨肉瘤，高风险全部和AML。 药代动力学 大型糖治疗和从移植生物学得出的数据的研究 和II阶段研究提供的机会迄今不容易 可用于使用药物的时间监测的高剂量方案 动力学以利用药物救援方案，例如高剂量 MTX带有叶酸营救或摩根输注后消融后输注 治疗。 佛罗里达大学的骨髓移植单元将 继续（1）进行高风险的同种异体移植研究 全部和AML，在第一次缓解旨在提出有关问题的问题 调理方案和免疫恢复，以及（2）使用自体 骨髓救援术后的巨糖治疗与药代动力学数据相结合 对于复发/抗性实体瘤，即尤因的肉瘤，神经母细胞瘤， 非霍奇金的淋巴瘤，脑肿瘤，霍奇金病和威尔姆斯肿瘤。 研究努力将包括将组织学和免疫学关联 与全部和神经母细胞瘤一样，具有治疗反应的特征。 所有的 小组努力将包括积极参与正在进行的和新的参与 开发的协议，包括多机构的成骨肉瘤 学习。 努力在科学参与方面也很有意义 调查包括外科医生和放射治疗师以及识别 其他代表35-40的卫星 患者/年，建立农村转诊，以维持家庭护理和 医疗中心的沟通，并建立全面的社会心理 支持系统。